HAVCR2 and neoplasm: Immune checkpoint blockade with αPD-L1 or double αPD-L1/αTIM-3 therapeutic antibody (because TIM-3 was also expressed on OT1 TSE TILs; Fig. 4e) did not improve tumor control by orthogonal ACT (Fig. 5a).